In November, Thermo Fisher Scientific introduced a fully integrated next generation sequencing (NGS) platform called the Ion Torrent Genexus System, and now the company has said that system will be able to run the Ion Torrent Oncomine Myeloid Research Assay next year. The purpose of the Genexus System is to make the genomic profiling process quicker and easier with its automated workflow which can produce results within 24 hours, making it more convenient for clinical researchers to examine myeloid malignancies with the least possible tissue sample contribution and manual involvement.
Thermo Fisher’s VP of product management for clinical next-generation sequencing and oncology, Andy Felton, stated: "The Genexus System holds promise to redefine the genomic profiling paradigm. We have heard significant interest from our customers in the potential to run our Oncomine Myeloid Research Assay on the new platform. Delivering on that need will mean that haematology and oncology labs can quickly get the results they need."
“Genexus System advancing genomic profiling.“
Western University’s associate professor of pathology and laboratory medicine as well as head of the Molecular Diagnostics Division in the Department of Pathology and Laboratory Medicine at London Health Sciences Centre, Bekim Sadikovic, stated: "For the past 2 years we have been using Thermo Fisher's NGS technology to analyse myeloid samples, and the Oncomine Myeloid Research Assay provides a comprehensive assessment to identify relevant variants in a single step. Making this assay available on a platform that can deliver results in a single day would provide labs with the answers they need for key mutations such as FLT3-ITDs, TP53, CEBPA, NPM1, KIT, PML-RARA and other biomarkers."